Interrogating the pathogenesis of copd using metabolomics and genomics data

Active Grant Awarded Last action

Award ID
R01HL173613
Recipient
Awarding agency
Obligated
$1,510,006

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 32% complete
Place of performance
Charlottesville, VA 22904, USA

Award details come from USAspending.gov.

Description

Abstract
Chronic lower respiratory diseases, including chronic obstructive pulmonary disease (COPD), are the third leading cause of death worldwide. While cigarette smoking is a common risk factor for COPD, the risk of disease also increases with age, and the disease can progress despite smoking cessation. Treatment options for COPD are limited: existing pharmacologic therapies have at best a modest impact on mortality on a subset of patients. Thus, a better understanding of the molecular pathophysiology of COPD is needed to guide the development of new treatments. Large-scale genome-wide association studies (GWAS) of lung function, and COPD have identified >1,000 independent association signals. Some of these associations are coding and have downstream targets, such as ager and sftpd, that have been implicated as biomarkers and drug targets for COPD by gene expression and protein data. However, the downstream metabolic implications of these GWAS signals have been largely unexplored, and substantial evidence links metabolomic signatures to COPD. We are expanding our previously established predixcan method, which was designed for the integration of GWAS with gene expression loci, to incorporate metabolomics data. This new tool, termed metaboxcan, will extract more comprehensive mechanistic information from GWAS and unlock new insights into the pathophysiology of COPD. By applying a preliminary version of metaboxcan to the most recent and comprehensive multi-ancestry GWAS of lung function, we identified metabolic pathways that overlap with strong candidates of interest from our prior work, including long-chain fatty acid metabolism. In this proposal, we will continue to develop our metaboxcan method to incorporate additional metabolomic resources derived from individuals with COPD, as well as disease- free controls (aim 1). We will further apply metaboxcan to achieve enhanced interpretation of large-scale GWAS for pulmonary disease traits in nhlbi cohorts (aim 2) as well as perform validation studies of selected metabolites (aim 3). To accomplish these aims, we have assembled an interdisciplinary collaborative group representing expertise in statistical genetics, pulmonary epidemiology, integrative genomics, metabolomics, and pulmonary medicine. Completion of these aims will establish an expanded view of the metabolomic targets and pathways influenced by genetic variation for COPD, which will also provide a foundation for future drug development efforts.

Transactions

Action Obligated Date
Amendment $709,327
Amendment $0
Original award $800,679

Subawards

Subrecipient Amount Awarded
Center For Veterans Research & Education For the above proposal, which seeks to develop a suite of -Xcan methods through the integration of multiple -omics datasets to identify metabolic pathways… $64,233
Brigham & Womens Hospital Inc. In this grant, Dr. Cho, Dr. Moll, and the postdoctoral fellow will be responsible for providing and curating genome-wide association studies of COPD and lung… $430,706
The Regents Of The University Of Colorado Co-I Kechris-Mays will be responsible for the analysis on data from the COPDGene cohort. She will help oversee the design and implementation of the suite of… $141,453
The University Of Chicago Dr. Im will supervise the development of the Metaboxcan method, ensuring analysis quality, interpreting results, identifying roadblocks, and finding… $379,043
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University Dr. Russell Bowler will help with interpretation of Omics datasets, manuscript writing, and coordination with the studies and IRBs. He will also participate… $83,743

Quick answers

Who received award R01HL173613?

R01HL173613 was awarded to Rector & Visitors Of The University Of Virginia by National Heart Lung and Blood Institute (National Institutes of Health) on September 10, 2025.

How much is award R01HL173613 worth?

$1,510,006 has been obligated on R01HL173613.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award